Corrigendum to “A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report” [Eur J of Canc (2017) 206–225]

Gnekow, Astrid; Walker, David; Kandels, Daniela; Picton, Susan; Perilongo, Giorgio; Grill, Jacques; Stokland, Tore; Sandström, Per; Warmuth‐Metz, Monika; Pietsch, Torsten; Giangaspero, Felice; Schmidt, René; Faldum, Andreas; Kilmartin, Denise; Paoli, Angela De; Salvo, Gian Luca De

doi:10.1016/j.ejca.2017.11.017

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…17 The treatment paradigm consists of maximal safe surgical resection and subsequent adjuvant chemoradiotherapy for symptomatic or progressive residual disease. 18 The most widely used chemotherapy regimen consists of a combination of carboplatin and vincristine 7 that has been included in the latest LGG protocol elaborated by the SIOP, 19 with a 3-and 5-year progression-free survival rate of 68 ± 7% and 35% to 45%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, a combinational regimen of thioguanine, procarbazine, lomustine, and vincristine, monotherapy with etoposide, bevacizumab, temozolomide or weekly vinblastine [19][20][21][22][23] have been proposed, none of these proving to be superior to the standard of care. 1,20 Radiation therapy is currently limited to non-NF1 older children, because long-term radio-induced side effects on the developing nervous system, including cognitive impairment, have been extensively documented.…”

Section: Discussionmentioning

confidence: 99%

“…The most widely used chemotherapy regimen consists of a combination of carboplatin and vincristine 7 that has been included in the latest LGG protocol elaborated by the SIOP, 19 with a 3‐ and 5‐year progression‐free survival rate of 68 ± 7% and 35% to 45%, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience

Cacchione

Lodi

Carai

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Pediatric low‐grade gliomas (pLGGs) are the most frequent brain tumor in children. Adjuvant treatment, consisting in chemotherapy and radiotherapy, is often necessary if a complete surgical resection cannot be obtained. Traditional treatment approaches result in a significant long‐term morbidity, with a detrimental impact on quality of life. Dysregulation of the mitogen‐activated protein kinase (MAPK) pathway is the molecular hallmark of pLGGs and hyperactivation of the downstream mammalian target of rapamycin (mTOR) pathway is frequently observed. We report clinical and radiological results of front‐line treatment with everolimus in 10 consecutive patients diagnosed with m‐TOR positive pLGGs at the Bambino Gesù Children's Hospital in Rome, Italy. Median duration of treatment was 19 months (range from 13‐60). Brain magnetic resonance imaging showed stable disease in 7 patients, partial response in 1 and disease progression in 2. Therapy‐related adverse events were always reversible after dose reduction or temporary treatment interruption. To the best of our knowledge, this is the first report of everolimus treatment for chemo‐ and radiotherapy‐naïve children with pLGG. Our results provide preliminary support, despite low sample size, for the use of everolimus as target therapy in pLGG showing lack of progression with a manageable toxicity profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience

Cacchione

Lodi

Carai

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives

Rojas

Clementel

Giralt

et al. 2019

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The aim of the study is to analyse radiotherapy quality assurance (RTQA) processes in the treatment of paediatric central nervous system (CNS) tumours across Europe. Methods: The RTQA aspects of major past and current European trials for paediatric CNS tumours were reviewed based on study protocols and publications. A survey among radiation oncologists and paediatric oncologists about the practices of RTQA in paediatric CNS tumours across European countries was also performed. Results: Several (inter)national initiatives to implement RTQA are being developed across Europe, with an apparent paradigm shift from retrospective to prospective RTQA. Experts from 21 of 29 contacted countries responded to the survey. National consensus guidelines for paediatric CNS tumours are available in 10 of 21 countries. Twenty-one of 33 experts

show abstract

Pediatric low-grade gliomas: next biologically driven steps

et al. 2017

View full text Add to dashboard Cite

Despite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neuro-oncology due to comorbidities associated with these tumors and/or their treatments, and their propensity to multiply recurs. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The Second International Consensus Conference on Pediatric Low-Grade Gliomas held in Padua, Italy in 2016 was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications of our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted therapy into late-stage clinical trials for newly diagnosed cases. Methods for the diagnostic assessment of alterations in the Ras/mitogen-activated protein kinase pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion.

show abstract

Corrigendum to “A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report” [Eur J of Canc (2017) 206–225]

Cited by 5 publications

References 0 publications

Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience

Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives

Pediatric low-grade gliomas: next biologically driven steps

Contact Info

Product

Resources

About